Media

STELVIO Trial Shows Sustained Benefits for Emphysema Patients One Year After Treatment with Zephyr® Endobronchial Valves

Nordic Nanovector announces first patient enrolled in the last cohort (Arm 4) of expanded Phase 1/2 study of Betalutin® in NHL patients

Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled

Strongbridge Biopharma plc Reports First Quarter 2016 Financial Results

HealthCap’s 35th IPO as HealthCap VI company Wilson Therapeutics completes listing on Nasdaq OMX Stockholm

Nordic Nanovector announces an open Investigational New Drug application for new clinical study of Betalutin® in diffuse large B-cell lymphoma

Strongbridge Biopharma plc Announces Presentation at Bio€quity Europe 2016

Nordic Nanovector announces first patient enrolled in Arm 3 of expanded Phase 1/2 study of Betalutin® in NHL patients